These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Sphingosine kinase-1 mediates BCR/ABL-induced upregulation of Mcl-1 in chronic myeloid leukemia cells. Li QF; Huang WR; Duan HF; Wang H; Wu CT; Wang LS Oncogene; 2007 Dec; 26(57):7904-8. PubMed ID: 17599053 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover. Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551 [TBL] [Abstract][Full Text] [Related]
7. c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors. Huang HM; Liu JC J Cell Physiol; 2009 Mar; 218(3):568-74. PubMed ID: 19006173 [TBL] [Abstract][Full Text] [Related]
8. The effects of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate. Schuster C; Forster K; Dierks H; Elsasser A; Behre G; Simon N; Danhauser-Riedl S; Hallek M; Warmuth M Blood; 2003 Jan; 101(2):655-63. PubMed ID: 12393654 [TBL] [Abstract][Full Text] [Related]
9. Gallic acid downregulates matrix metalloproteinase-2 (MMP-2) and MMP-9 in human leukemia cells with expressed Bcr/Abl. Chen YJ; Chang LS Mol Nutr Food Res; 2012 Sep; 56(9):1398-412. PubMed ID: 22865631 [TBL] [Abstract][Full Text] [Related]
10. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063 [TBL] [Abstract][Full Text] [Related]
11. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169 [TBL] [Abstract][Full Text] [Related]
12. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536 [TBL] [Abstract][Full Text] [Related]
13. BCR-ABL alters the proliferation and differentiation response of multipotent hematopoietic cells to stem cell factor. Pierce A; Spooncer E; Ainsworth S; Whetton AD Oncogene; 2002 May; 21(19):3068-75. PubMed ID: 12082538 [TBL] [Abstract][Full Text] [Related]
14. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells. Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631 [TBL] [Abstract][Full Text] [Related]
15. Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition. Jacquel A; Colosetti P; Grosso S; Belhacene N; Puissant A; Marchetti S; Breittmayer JP; Auberger P Oncogene; 2007 Apr; 26(17):2445-58. PubMed ID: 17043649 [TBL] [Abstract][Full Text] [Related]
17. Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation. Barnes K; McIntosh E; Whetton AD; Daley GQ; Bentley J; Baldwin SA Oncogene; 2005 May; 24(20):3257-67. PubMed ID: 15735728 [TBL] [Abstract][Full Text] [Related]
18. BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia. Chu S; Li L; Singh H; Bhatia R Cancer Res; 2007 Jul; 67(14):7045-53. PubMed ID: 17638918 [TBL] [Abstract][Full Text] [Related]
19. Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines. Barnes DJ; De S; van Hensbergen P; Moravcsik E; Melo JV Leukemia; 2007 Mar; 21(3):421-6. PubMed ID: 17252018 [TBL] [Abstract][Full Text] [Related]
20. Erythropoietin overcomes imatinib-induced apoptosis and induces erythroid differentiation in TF-1/bcr-abl cells. Uchida M; Watanabe T; Kunitama M; Mori M; Kikuchi S; Yoshida K; Kirito K; Nagai T; Ozawa K; Komatsu N Stem Cells; 2004; 22(4):609-16. PubMed ID: 15277706 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]